Galectin Therapeutics Inc., a biopharmaceutical company at the clinical stage, is making strides in developing therapies for a variety of diseases, including cancer and fibrotic conditions. Among its most promising projects is belapectin (GR-MD-02), a unique galactoarabino-rhamnogalacturonan polysaccharide polymer that inhibits galectin-3 and is currently undergoing Phase III clinical testing to address liver fibrosis connected to non-alcoholic steatohepatitis cirrhosis and fatty liver disease. The firm manages the joint venture Galectin Sciences, LLC, co-run with SBH Sciences, Inc., which is responsible for exploring small molecule competitors of galectin-3 for oral administration. The company, previously named Pro-Pharmaceuticals, Inc., shifted its name to Galectin Therapeutics, Inc. in May 2011. Founded in 2000, Galectin Therapeutics Inc. has its headquarters in Norcross, Georgia.
Galectin Therapeutics Inc.'s ticker is GALT
The company's shares trade on the NASDAQ stock exchange
They are based in Norcross, Georgia
There are 1-10 employees working at Galectin Therapeutics Inc.
It is https://galectintherapeutics.com/
Galectin Therapeutics Inc. is in the Healthcare sector
Galectin Therapeutics Inc. is in the Biotechnology industry
The following five companies are Galectin Therapeutics Inc.'s industry peers: